CME Presentations

Atopic Derm Point/Counterpoint

Presentations

Speakers

  • Angela Lamb, MD

    Angela Lamb, MD

    Angela Lamb, MD

    Associate Professor, Vice Chair of Clinical Operations

    Angela Lamb, MD is a New York City dermatologist who treats patients of all ages for acne, atopic dermatitis, skin-cancer detection, and numerous other skin disorders, including many for patients undergoing cancer treatment. Serving in several leadership roles at Mount Sinai, Dr. Lamb is director of the Westside Mount Sinai Dermatology Faculty Practice and an associate professor of dermatology. She was recently promoted to System Vice Chair of Dermatology Clinical Operations and Strategy and also serves as medical director of the Mount Sinai Doctors Patient Access Center. Dr. Lamb is intent on partnering with her patients to determine the best course of treatment and ongoing care.

    Session Appearances

    Atopic Dermatitis and Its Comorbid Conditions: How Knowing About Them Will Help Guide Your Treatment Decisions

  • Anne Marie Singh, MD

    Anne Marie Singh, MD

    Anne Marie Singh, MD

    Associate Professor, Interim Division Head, Division of Allergy, Immunology and Rheumatology

    Anne Marie Singh, MD is an associate professor of pediatrics; interim division chief of the Division of Allergy, Immunology and Rheumatology; and director of the Food Allergy Research and Education Clinical Research Center of Distinction at the University of Wisconsin School of Medicine and Public Health. She also has affiliate appointments in the Departments of Dermatology, Medical Microbiology and Immunology, and Food Research. Dr. Singh’s research is focused on advancing the clinical care of patients with early atopic diseases, including atopic dermatitis and food allergy, as well as mechanistic studies on the effects of environmental and microbial exposures on development of allergic diseases. She is leading the Childhood Allergy and NeOnatal Environment (CANOE) birth cohort as part of NIH’s Environmental Childhood Health Outcomes (ECHO) study.

    Session Appearances

    Atopic Dermatitis and Its Comorbid Conditions: How Knowing About Them Will Help Guide Your Treatment Decisions

CME Information

Global LogoPQH Logo

Atopic Dermatitis and Its Comorbid Conditions: How Knowing About Them Will Help Guide Your Treatment Decisions

This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC, in collaboration with the Asthma and Allergy Foundation of America (AAFA).

ACKNOWLEDGEMENT

This activity is supported by an independent medical education grant from Sanofi and Regeneron Pharmaceuticals.

DATE OF RELEASE/EXPIRATION

October 20th 2023. Expires October 20th, 2024

TARGET AUDIENCE

The intended audience for this program is dermatologists, allergists, immunologists, advanced specialty practitioners, pharmacists, and nurses.

STATEMENT OF NEED/PROGRAM OVERVIEW

Interviews with patients living with atopic dermatitis (AD) found that medication safety was the single most important factor in their treatment decisions. However, confusion remains regarding the mechanisms of the disease and the impact of comorbidities when deciding on a treatment plan for AD. Education can bring clinicians up to date with the most current evidence on available therapies for moderate-to-severe AD, long-term safety, and associated impacts on quality of life. The recently published American Academy of Dermatology (AAD) recommendations on awareness of comorbidities in AD management can also help clinicians choose the most effective and safest options from the evidence-based treatment paradigm.

Join an expert panel of dermatologists and allergists to discuss the impact of comorbidities on moderate-to-severe AD treatment decisions, along with the importance of medication safety in treatment decisions. Panelists will discuss how to help patients reach long-term control of their disease and review the benefits, limitations, and risks associated with evidence-based treatment of AD.

EDUCATIONAL OBJECTIVES

After completing this activity, the participant should be better able to:
  • Evaluate current evidence, including long-term safety data and impact on quality of life, for currently approved agents for the treatment of moderate-to-severe AD
  • Explain how the presence of comorbidities can influence the treatment of moderate-to-severe AD

PHYSICIAN ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.

PHYSICIAN CREDIT DESIGNATION

Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ESTIMATED TIME TO COMPLETE

This activity should take approximately 1 hour to complete.

INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FEE INFORMATION & REFUND/CANCELLATION POLICY

There is no fee for this educational activity.

DISCLOSURES OF RELEVANT FINANCIAL RELATIONSHIPS

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global.  All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.  

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:
Name of Faculty or Presenter Reported Financial Relationship
Angela J. Lamb, MD
Associate Professor
Vice Chair of Clinical Operations, Department of Dermatology
Icahn School of Medicine at Mount Sinai 		Nothing to Disclose
Anne Marie Singh, MD
Associate Professor
Interim Division Head, Division of Allergy, Immunology and Rheumatology
Department of Pediatrics
University of Wisconsin School of Medicine and Public Health 		Consulting Fee (e.g., Advisory Board): Incyte, Genentech
Other: Siolta Therapeutics - data safety monitoring board

The planners and managers at Global Education Group and PlatformQ Health Education, LLC have no relevant financial relationships to disclose.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support:

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com

Technical Support:

For any technical issues or issues with your CME Certificate, please contact, ImmunologyLive, at 877-394-1306 or at Support@ImmunologyLive.com.